Evaluation of VEFG and TPA levels and some biochemical marker in sera of women with breast cancer

Breast cancer is a common malignancy and a major cause of death in women. Breast cancer, which accounts for 25% of all malignancies, is the most common malignancy among women globally .There were more than 2 million cases of breast cancer in 2018, With a mortality rate of 23% due to cancer, breast cancer has grown to be a serious threat to women's health in Iraq, It is currently the second largest cause of mortality for women, after only cardiovascular disease. According to the most current Iraqi Cancer Registry, there were 21,101 new cancer cases documented in 2012 among an estimated 32,500,000 persons, with males accounting for 9,268 and women contributing for 11,833. In women, the incidence rate is practically uniformly rising, accounting for around 15% of all cancer fatalities. From November 1st, 2022, to June 30th, 2023, this study was conducted at the oncology center in Kirkuk City, Iraq. This research included 90 women ranging in age from 25 to 55 years. 56 sick and 34 healthy persons. Between November 1st, 2022, to June 30th, 2023, women with breast cancer were collected from Kirkuk Oncology Center. The body weight and height were measured for the calculation of the body mass index . this study show that the mean of BMI of patient is 56% for women breast cancer, whil control is 34%.Ablood samples were collection for each women included in this study for the estimation of VEGF, HPA, HPI ,Ca15-3, LDH, ALP , Vit.D, BMI and Age. This study aims to assess the role of VEGF in women with breast cancer. The mean serum level of VEGV was significantly higher in women with breast cancer compared to control(0.51805 and 0. 27541)ng/L, while the ii mean serum level of HPA was higher in women with breast cancer compared to control (0.42584 and 0.21926) ng/ml, while the mean serum level of HPI was higher in women with breast cancer compared to control (0.55968 and 0.30626) ng/ml. The mean serum level of CA 15-3 was higher in women with breast cancer (32.4718IU/ml) as compared with the control group (6.0632 IU/ml). The mean serum level of vitamin D was significantly reduced in women with breast cancer (14.7446 ng/ml) as compared with the control group (35.2053 ng/ml). The serum level of LDH activity was significantly elevated in breast cancer women (463.20 U/l) as compared with healthy women (232.38U/l). While the mean ALP activity in serum was significantly elevated in breast cancer women was (173.34 U/l) as compared with healthy women which was (103.35U/l)